News
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting ...
NANJING, China I May 31, 2025 I Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") today announced the presentation of groundbreaking clinical data from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback